Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia

International Journal of Antimicrobial Agents

Volumn 31, Issue 5, 2008, Pages 452-457

  Kanbayashi, Yuko ^a,b   Nomura, Kenichi ^c,d   Fujimoto, Yoshiko ^c   Shimura, Kazuho ^c   Shimizu, Daisuke ^c   Okamoto, Kousuke ^b   Matsumoto, Yosuke ^c   Horiike, Shigeo ^c   Shimazaki, Chihiro ^c   Takagi, Tatsuya ^b,e,f   Taniwaki, Masafumi ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY   (Japan)

^d Kyoto Prefectural Institute of Public Health and Environment   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f Research Collaboration Center on Emerging and Re emerging Infections   (Japan)

Author keywords

Febrile neutropenia; Itraconazole; Population pharmacokinetics; Prophylaxis

Indexed keywords

ITRACONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); COVARIANCE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGY; HUMAN; JAPANESE; LARGE SCALE PRODUCTION; MALE; PHARMACOKINETICS; PILOT STUDY; POPULATION; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY;

AGED; ANTIFUNGAL AGENTS; CHEMOPREVENTION; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PLASMA; TISSUE DISTRIBUTION;

EID: 41949102794     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.12.017     Document Type: Article

References (33)

1. Yoshida M., Tsubaki K., Kobayashi T., Tanimoto M., Kuriyama K., Murakami H., et al. Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. Int J Hematol 70 (1999) 261-267
2. Wald A., Leisenring W., van Burik J.A., and Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 (1997) 1459-1466
3. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91 (2006) 1068-1075
4. Denning D.W., Tucker R.M., Hanson L.H., and Stevens D.A. Treatment of invasive aspergillosis with itraconazole. Am J Med 86 (1989) 791-800
5. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 23 (2004) 105-112
6. Ascioglu S., de Pauw B.E., and Meis J.F. Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int J Antimicrob Agents 15 (2000) 159-168
7. Oren I., Rowe J.M., Sprecher H., Tamir A., Benyamini N., Akria L., et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38 (2006) 127-134
8. Glasmacher A., Cornely O., Ullmann A.J., Wedding U., Bodenstein H., Wandt H., et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57 (2006) 317-325
9. Grant S.M., and Clissold S.P. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37 (1989) 310-344
10. Glasmacher A., Molitor E., Hahn C., Bomba K., Ewig S., Leutner C., et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 12 (1998) 1338-1343
11. Nomura K., Fujimoto Y., Ohshiro M., Kobayashi T., Yamashita M., Tsutsumi Y., et al. Prophylactic effect of itraconazole against fungal infection in either patients with lymphoma receiving salvage chemotherapy or elderly patients. Progr Med 27 (2007) 117-121 [in Japanese]
12. Glasmacher A., Hahn C., Molitor E., Marklein G., Sauerbruch T., and Schmidt-Wolf I.G. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42 (1999) 591-600
13. Simon A., Besuden M., Vezmar S., Hasan C., Lampe D., Kreutzberg S., et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer 15 (2007) 213-220
14. Glasmacher A., and Prentice A.G. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 56 suppl. 1 (2005) i23-i32
15. Glasmacher A., Prentice A., Gorschlüter M., Engelhart S., Hahn C., Djulbegovic B., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21 (2003) 4615-4626
16. Marr K.A., Crippa F., Leisenring W., Hoyle M., Boeckh M., Balajee S.A., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 527-533
17. Winston D.J., Maziarz R.T., Chandrasekar P.H., Lazarus H.M., Goldman M., Blumer J.L., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138 (2003) 705-713
18. Schuler U., Bammer S., Aulitzky W.E., Binder C., Böhme A., Egerer G., et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 30 (2007) 185-191
19. Boogaerts M.A., Verhoef G.E., Zachee P., Demuynck H., Verbist L., and De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32 (1989) 103-108
20. Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party. Lancet 1991; 337:1577-80.
21. Pandya N.A., Atra A.A., Riley U., and Pinkerton C.R. Role of itraconazole in haematology/oncology. Arch Dis Child 88 (2003) 258-260
22. Poirier J.-M., Hardy S., Isnard F., Tilleul P., Weissenburger J., and Cheymol G. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther Drug Monit 19 (1997) 525-529
23. Foot A.B., Veys P.A., and Gibson B.E. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 24 (1999) 1089-1093
24. Hennig S., Wainwright C.E., Bell S.C., Miller H., Friberg L.E., and Charles B.G. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 45 (2006) 1099-1114
25. Hennig S., Waterhouse T.H., Bell S.C., France M., Wainwright C.E., Miller H., et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 63 (2007) 438-450
26. Conway S.P., Etherington C., Peckham D.G., Brownlee K.G., Whitehead A., and Cunliffe H. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 53 (2004) 841-847
27. Mouton J.W., van Peer A., de Beule K., Van Vliet A., Donnelly J.P., and Soons P.A. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 50 (2006) 4096-4102
28. Waterhouse T.H., Redmann S., Duffull S.B., and Eccleston J.A. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn 32 (2005) 521-545
29. Uno T., Shimizu M., Sugawara K., and Tateishi T. Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 28 (2006) 526-531
30. Lindbom L., Ribbing J., and Jonsson E.N. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75 (2004) 85-94
31. Lindbom L., Pihlgren P., and Jonsson E.N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79 (2005) 241-257
32. ® (itraconazole) oral solution 1% second rev. 2006 [in Japanese]. http://www.janssen.co.jp/inforest/portalexternal/diviewitemeventdatafiledownload?paf_gear_id=2200031&cid=cnt24924 [accessed 17 January 2008].
33. Conte Jr. J.E., Golden J.A., Kipps J., McIver M., and Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob Agents Chemother 48 (2004) 3823-3827